Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy (S19.005)

20242 citationsJournal Articlegreen Open Access

Authors

Jacqueline A. French · New York University

Roger J. Porter · California University of Pennsylvania

Emilio Perucca · University of Melbourne

Martin J. Brodie · University of Glasgow

Michael A. Rogawski · University of California, Davis

Cynthia L. Harden · Xenon Pharmaceuticals (Canada)

Jenny Qian

Abstract

To report interim 18-month data from an ongoing, long-term, open-label extension (OLE) of a Phase 2b study (X-TOLE) of XEN1101 in adults with focal onset seizures (FOS).

Topics & Keywords

Ion channel regulation and function Epilepsy research and treatment Cardiac electrophysiology and arrhythmias

Publication Details

Published in: Neurology

Volume 102, Issue 7_supplement_1

DOI: 10.1212/wnl.0000000000204537

Field-Weighted Citation Impact: 0.49

Command Palette

Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy (S19.005)

Authors

Abstract

Topics & Keywords

Publication Details